Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 534.5 DKK -1.35% Market Closed
Market Cap: 101B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Equity Peer Comparison

Comparables:
ZEAL
ASND
B
BAVA
F
FLUO
BIOPOR

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Equity
kr31B
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
33%
Zealand Pharma A/S
CSE:ZEAL
Total Equity
kr9.4B
CAGR 3-Years
89%
CAGR 5-Years
58%
CAGR 10-Years
41%
Ascendis Pharma A/S
NASDAQ:ASND
Total Equity
-€321.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Total Equity
kr10.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
27%
F
Fluoguide AS
STO:FLUO
Total Equity
kr12.7m
CAGR 3-Years
42%
CAGR 5-Years
351%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Equity
kr104.8m
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
12%

See Also

What is Genmab A/S's Total Equity?
Total Equity
31B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Equity amounts to 31B DKK.

What is Genmab A/S's Total Equity growth rate?
Total Equity CAGR 10Y
33%

Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Genmab A/S have been 15% over the past three years , 30% over the past five years , and 33% over the past ten years .

Back to Top